Publication: Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System: the cefiderocol example.
No Thumbnail Available
Identifiers
Date
2022-05-20
Authors
Calleja, Miguel Ángel
Badia, Xavier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The reimbursement of medicines by the Spanish National Health System (NHS) is based on a set of criteria included in the Royal Legislative Decree 1/2015 (RDL 1/2015). The Interministerial Committee on Pricing of Medicines and Healthcare Products (CIPM) is responsible for the final price and reimbursement (P&R) decision, including on its resolutions the criteria listed in the law by which the reimbursement of a drug is approved or denied. Nevertheless, the information behind its reasoning is not provided. The present study aims to characterize the P&R criteria of the RDL 1/2015 through criteria definitions from other countries to improve the P&R evaluation in Spain. A multidisciplinary experts panel with relevant experience in drug evaluation and decision making at national, regional, and local level in Spain was selected for this study. A literature review to characterize the criteria listed in the RDL 1/2015 was performed based on the most relevant and recognized Health Technology Assessment (HTA) agencies in Europe, UK, and Canada. Eventually, a feasibility study was performed to evaluate the novel drug cefiderocol using the characterized criteria, including a reflective discussion of the results. Consensus was reached among the multidisciplinary experts on the characterization of the criteria set by the law. The feasibility of their application to a new drug was exploratory, notwithstanding it showed the potential to improve the transparency as well as to offer a more structured rationale for the CIPM to evaluate the inclusion of new drugs in the Spanish NHS.
Description
MeSH Terms
Cephalosporins
Costs and Cost Analysis
Europe
Feasibility Studies
Technology Assessment, Biomedical
Costs and Cost Analysis
Europe
Feasibility Studies
Technology Assessment, Biomedical
DeCS Terms
CIE Terms
Keywords
Cefiderocol, Drug evaluation, P&R criteria characterization, P&R decision-making criteria, Pricing and reimbursement